Literature DB >> 19123985

Choline autoradiography of human prostate cancer xenograft: effect of castration.

Hossein Jadvar1, Alparslan Gurbuz, Xiankui Li, Antranik Shahinian, Peter S Conti.   

Abstract

The purpose of this study was to investigate the effects of castration and tracer uptake time interval on the level of radiolabeled choline accumulation in murine-implanted human prostate tumor xenografts using quantitative autoradiography. We implanted androgen-dependent (CWR22) and androgen-independent (PC3) human prostate cancer cells in castrated (n = 9) and noncastrated (n = 9) athymic male mice and allowed tumors to grow to 1 cm3. The mice were euthanized at 5, 10, and 20 minutes after injection of 5 microCi [14C]-choline. Mice were prepared for quantitative autoradiography with density light units of viable tumor sections converted to units of radioactivity (nCi/mm2) using calibration. Two-group comparisons were performed using a two-tailed Student t-test with unequal variance and with a significance probability level of less than .05. Two-group comparisons between the means of the tracer uptake level for each tumor type at each of three time points for each of two host types showed that (1) the level of tracer localization in the two tumor types was affected little in relation to the host type and (2) PC3 tumor uptake level tended to increase slowly with time only in the noncastrated host, whereas this was not observed in the castrated host or with CWR22 tumor in either host type. The uptake time interval and castration do not appear to significantly affect the level of radiolabeled choline uptake by the human prostate cancer xenograft.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19123985      PMCID: PMC2621313     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  30 in total

1.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

Authors:  M Picchio; C Messa; C Landoni; L Gianolli; S Sironi; M Brioschi; M Matarrese; D V Matei; F De Cobelli; A Del Maschio; F Rocco; P Rigatti; F Fazio
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

2.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

3.  Visualization of prostate cancer with 11C-choline positron emission tomography.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2002-07       Impact factor: 20.096

4.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

5.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

6.  Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

Authors:  Daniela B Husarik; Raymond Miralbell; Markus Dubs; Hubert John; Olivier T Giger; Albert Gelet; Tibor Cservenyàk; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

7.  Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model.

Authors:  Kristine Glunde; Tariq Shah; Paul T Winnard; Venu Raman; Tomoyo Takagi; Farhad Vesuna; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.

Authors:  David T Price; R Edward Coleman; Ray P Liao; Cary N Robertson; Thomas J Polascik; Timothy R DeGrado
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

9.  The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.

Authors:  I Igerc; S Kohlfürst; H J Gallowitsch; S Matschnig; E Kresnik; I Gomez-Segovia; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-11       Impact factor: 9.236

10.  Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

Authors:  Eija Sutinen; Martti Nurmi; Anne Roivainen; Matti Varpula; Tuula Tolvanen; Pertti Lehikoinen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-20       Impact factor: 9.236

View more
  7 in total

1.  Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

Authors:  Kimy M Emonds; Johannes V Swinnen; Wytske M van Weerden; Frank Vanderhoydonc; Johan Nuyts; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.

Authors:  Rutger J Dost; Andor W J M Glaudemans; Anthonius J Breeuwsma; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

Review 4.  Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2010-12-13       Impact factor: 10.057

5.  Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Authors:  Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

Review 6.  Molecular imaging of prostate cancer: a concise synopsis.

Authors:  Hossein Jadvar
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

7.  Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model.

Authors:  Kimy M Emonds; Johannes V Swinnen; Evelyne Lerut; Michel Koole; Luc Mortelmans; Felix M Mottaghy
Journal:  EJNMMI Res       Date:  2013-04-24       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.